Ruzanna Papyan, Chief of Pediatric Oncology Department at PCBDC of Armenia, Clinical Research Physician at Immune Oncology Research Institute, shared a post on LinkedIn:
“‘The Price of Survival: Global Inequities in Anti-GD2 Immunotherapy for Neuroblastoma’ has been accepted for publication in Pediatric Blood and Cancer.
This feels like a meaningful end-of-year gift —not just for me, but for everyone who believes that where a child is born should not determine their chance of survival.
I am forever grateful to my incredible co-authors and Global Neuroblastoma Network team for their dedication and help. A special thanks to Scott Howard, Katherine Matthay, and my forever mentor Gevorg Tamamyan, for their guidance, trust, and steady encouragement.
A sincere thank-you to the reviewers—whoever and wherever you are—for your thoughtful comments. You challenged us, improved the paper, and absolutely made it stronger.
This article highlights disparities in access to anti-GD2 immunotherapy worldwide and calls for concrete, actionable solutions—especially for children treated in low- and middle-income countries.
I will share the full article link as soon as it becomes available.
Wishing everyone a peaceful holiday season and a new year filled with collaboration, equity, and hope for our patients and families.”
More posts featuring Ruzanna Papyan.